July 2025 Prescription Drug Affordability Board Meeting

• Date and time: July 28th, 2025 2:00 pm
• Address:

  Miller Senate Building, William Amoss Room, 4th Floor
  11 Bladen Street
  Annapolis, MD 21401
  United States

Public Comment

The Board has set aside an opportunity for public comment during the meeting. Public comments must concern an agenda item and are limited to one minute and thirty seconds per comment. If you are interested in registering to make a public comment, please email [email protected]​ no later than the close of business on Wednesday, July 23, 2025, and provide:

1. Your name
2. Your address
3. The agenda item your comment will address. PDAB staff will reach out to you directly to confirm your reservation or provide additional detail.

Written Comment

The public may also submit written comments on the Board's pending decisions, or general comments regarding the Board's work, to [email protected]. Please include in the subject line: July 2025 Board Meeting Comments. Please submit any written comments concerning this agenda no later than the close of business on Wednesday, July 23, 2025.

Agenda and Meeting Materials

• ​Agenda - PDF - 171.81 KB
• Minutes - PDF - 176.1 KB
• Meeting Recording
• Overview of Cost Review Study Process and Policy Review Process- Presentation - PDF - 289.46 KB
• Farxiga Cost Review Study- Presentation - PDF - 2.37 MB
• Jardiance Cost Review Study- Presentation - PDF - 2.58 MB

Dossier Information (Posted 7/18/2025)- Updated - Farxiga

• July 18, 2025 Farxiga Dossier​- updated 7/23/2025​ - PDF - 2.11 MB
  • 7.28.2025 Farxiga Exhibit 1 - PDF - 242.27 KB
  • ​Exhibit 2 RFI Submissions (NON-PUBLIC--TRADE SECRET, ​CONFIDENTIAL, AND PROPRIE​TARY) ​​
  • Exhibit 3​ ​Farxiga Therapeutic Alternative Pricing REDACTED - XLSX - 315.17 KB
  • Exhibit 4 Farxiga Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics - XLSX - 150.25 KB
  • Exhibit 5
    • Exhibit 5A Farxiga Summary of Cost Effectiveness Analyses - XLSX - 27.66 KB
    • Exhibit 5B Farxiga Summary of Comparative Effectiveness Research   - XLSX - 64.44 KB
  • Exhibit 6
    • ​Exhibit 6A Written Comments (60-day COMAR 14.01.04.05C(2)) - PDF - 845.68 KB
    • Exhibit 6B Written Comments (Request October 28, 2024) - PDF - 211.1 KB
    • Exhibit 6C Written Comments (Request January 27, 2025) - PDF - 666.02 KB
    • Exhibit 6D Written Comments (Request June 18, 2025) - PDF - 1.52 MB

Dossier Information (Posted 7/18/2025)- Updated- Jardiance

• ​​July 18, 2025 Jardiance Dossier- updated 7/23/2025 - PDF - 2.16 MB
  • Exhibit 1 Pricing History REDACTED - PDF - 220.37 KB
  • ​Exhibit 2 RFI Submissions (NON-PUBLIC--TRADE SECRET, ​CONFIDENTIAL, AND PROPRIETARY) ​
  • Exhibit 3​ ​Jardiance Therapeutic Alternative Pricing REDACTED - XLSX - 315.15 KB
  • Exhibit 4 Jardiance Therapeutic Alternative Medical Claims Data Base (MCDB) Statistics - XLSX - 150.29 KB
  • Exhibit 5
    • Exhibit 5A Jardiance Summary of Cost Effectiveness Analyses - XLSX - 117.71 KB
    • Exhibit 5B Jardiance Summary of Comparative Effectiveness Research   - XLSX - 60.49 KB
  • Exhibit 6
    • Exhibit 6A Written Comments (60-day COMAR 14.01.04.05C(2)) - PDF - 844.12 KB
    • Exhibit 6B Written Comments (Request October 28, 2024) - PDF - 318.65 KB
    • Exhibit 6C Written Comments (Request January 27, 2025) - PDF - 676.4 KB
    • Exhibit 6D Written Comments (Request June 18, 2025) - PDF - 820.19 KB

Comments Received from the following entities:​

Written comment Packet - PDF - 816.58 KB

• Aimed Alliance
• Diabetes Patient Advocacy Coalition
• Let My Doctors Decide Action Network
• The Board of Garrett County Commissioners

Comments Received after the deadline

• Color of Gastrointestinal Illnesses (COGI) - PDF - 864.64 KB